Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China

被引：0

作者：

Rui Hua

Fei Kong

Guangming Li

Xiaofeng Wen

Yuexin Zhang

Xingxiang Yang

Chenxin Meng

Wen Xie

Yongfang Jiang

Xiaozhong Wang

Xueji Han

Yan Huang

Qing Mao

Jiefei Wang

Yujuan Guan

Jiayu Chen

Yingjie Ma

Qingfang Xiong

Hong Ma

Xuebing Yan

Huiying Rao

Yingren Zhao

Tong Sun

Liying Zhu

Xiaorong Mao

Jianqi Lian

Guojiong Deng

Yongning Xin

Yifei Wang

Yinong Ye

Bin Xu

Hainv Gao

Youwen Tan

Dongliang Li

Dongliang Yang

Minghua Su

Xiaomeng Zhang

Jie Min

Xinsheng Shi

Lai Wei

Junqi Niu

机构：

[1] The First Hospital of Jilin University,Center of Infectious Diseases and Pathogen Biology, Department of Hepatology, Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, State Key Laboratory of Zoonotic Disease

[2] Beijing Tsinghua Changgung Hospital,Tangdu Hospital

[3] Zhengzhou Sixth People’s Hospital,Union Hospital, Tongji Medical College

[4] Liuzhou People’s Hospital,undefined

[5] The First Hospital Affiliated to Xinjiang Medical University,undefined

[6] Sichuan Provincial People’s Hospital,undefined

[7] The Sixth People’s Hospital of Shenyang,undefined

[8] Beijing Ditan Hospital Affiliated with Capital Medical University,undefined

[9] The Second Xiangya Hospital of Central South University,undefined

[10] Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine,undefined

[11] Affiliated Hospital of Yanbian University,undefined

[12] Xiangya Hospital,undefined

[13] Central South University,undefined

[14] The First Affiliated Hospital of Army Military Medical University,undefined

[15] Shanghai Public Health Clinical Center,undefined

[16] Guangzhou Eighth People’s Hospital,undefined

[17] The 940th Hospital of Joint Logistics Support Force of PLA,undefined

[18] Zhengzhou People’s Hospital,undefined

[19] The Second Hospital of Nanjing,undefined

[20] Beijing Friendship Hospital Affiliated with Capital Medical University,undefined

[21] The Affiliated Hospital of Xuzhou Medical University,undefined

[22] Peking University People’s Hospital,undefined

[23] The First Affiliated Hospital of Xi’an Jiaotong University,undefined

[24] The Fifthth People’s Hospital of Wuxi,undefined

[25] The Fourth Affiliated Hospital of Harbin Medical University,undefined

[26] The First Hospital of Lanzhou University,undefined

[27] The Fourth Military Medical University of the PLA,undefined

[28] Jiangyin People’s Hospital,undefined

[29] Qingdao Municipal Hospital,undefined

[30] Tonghua Central Hospital,undefined

[31] Foshan First People’s Hospital,undefined

[32] Beijing You’an Hospital Affiliated with Capital Medical University,undefined

[33] Shulan (Hangzhou) Hospital,undefined

[34] The Third People’s Hospital of Zhenjiang,undefined

[35] The 900Th Hospital of Joint Logistics Support Force of PLA,undefined

[36] Huazhong University of Science and Technology,undefined

[37] The First Affiliated Hospital of Guangxi Medical University,undefined

[38] Nanjing Sanhome Pharmaceutical Co.,undefined

[39] Ltd,undefined

来源：

Infectious Diseases and Therapy | 2023年 / 12卷

关键词：

Alfosbuvir; Daclatasvir; Hepatitis C virus; China;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2595 / 2609

页数：14

共 107 条

[1]

Sievert W(2011)A systematic review of hepatitis C virus epidemiology in Asia Australia and Egypt Liver Int 31 61-80

[2]

Altraif I(2017)Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution Virol J 14 41-485

[3]

Razavi HA(2022)Trends in the disease burden of HBV and HCV infection in China from 1990–2019 Int J Infect Dis 122 476-1176

[4]

Abdo A(2018)Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: results from a phase 3b study in China J Gastroenterol Hepatol 33 1168-132

[5]

Ahmed EA(2018)Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study Hepatol Int 12 126-452

[6]

Alomair A(2017)Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy Hepatol Commun 1 439-464

[7]

Zhang Y(2022)Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: an open-label, phase 2 study J Viral Hepat 29 455-5071

[8]

Chen LM(2014)Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect J Med Chem 57 5057-725

[9]

He M(2015)Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1 N Engl J Med 373 714-511

[10]

Yue TT(2018)EASL recommendations on treatment of hepatitis C 2018 J Hepatol 69 461-1318

← 1 2 3 4 5 6 7 8 9 10 →